I would respectfully submit: no, not really. Lots of drugs make it to Phase 3 that really haven't shown much activity to date and go on to fail in Phase 3. Small-cap companies that have limited assets have an incentive to continue to carry on trials of their key drug, regardless of clinical robustness to date and chances of success going forward, lest they not look viable (that has been called Zebra's Law on here).
Believe me, I hope it works for patients and PPHM investors. I'm just very skeptical based on the limited evidence to date.